News
SPHRF
0.330
NaN%
--
Starpharma Seeks ASX Quotation for Over 1 Million New Shares
TipRanks · 13h ago
UBS Group Ceases to Be Substantial Shareholder in Starpharma
TipRanks · 03/12 02:39
Starpharma Ramps Up DEP® Partnerships and Radiopharma Pipeline as Viraleze™ Sales Surge
TipRanks · 01/29 02:27
Starpharma Seeks ASX Quotation for 1.69 Million New Ordinary Shares
TipRanks · 01/07 02:18
Starpharma Announces Lapse of 381,810 Performance Rights
TipRanks · 01/07 02:17
Starpharma CEO Receives New Performance Rights
TipRanks · 12/17/2025 03:28
Starpharma Issues Unquoted Securities to Boost Employee Incentives
TipRanks · 12/17/2025 03:18
Starpharma Announces Successful 2025 AGM Results
TipRanks · 11/14/2025 05:30
Starpharma Announces Strategic Partnerships and Growth at AGM
TipRanks · 11/14/2025 03:08
Starpharma Secures Key Partnerships and Advances Strategic Initiatives in Q1 FY26
TipRanks · 10/28/2025 00:09
Starpharma Receives $5.5 Million Upfront Payment from Genentech for Oncology Collaboration
TipRanks · 10/22/2025 01:59
Starpharma Showcases Strategic Advances in Oncology Drug Delivery
TipRanks · 10/21/2025 04:57
Starpharma Director Increases Shareholding
TipRanks · 10/21/2025 02:48
Starpharma Announces 2025 AGM with Hybrid Participation
Barchart · 10/13/2025 19:30
Starpharma Director’s Performance Rights Adjusted
Barchart · 10/06/2025 20:14
Radiopharm Theranostics Partners with Starpharma to Develop Novel Radiopharmaceutical Using DEP® Platform
Reuters · 09/30/2025 10:05
Radiopharm and Starpharma Collaborate on Novel Cancer Therapy
TipRanks · 09/30/2025 03:08
Starpharma Partners with Radiopharm to Develop Novel Radiotherapy Asset
TipRanks · 09/30/2025 03:07
Starpharma Holdings Limited Announces Collaboration and License Agreement with Genentech for Cancer Therapy Development
Reuters · 09/22/2025 11:30
STARPHARMA ANNOUNCES A COLLABORATION AND LICENSE AGREEMENT WITH GENENTECH
Reuters · 09/22/2025 11:30
More
Webull provides a variety of real-time SPHRF stock news. You can receive the latest news about Starpharma Holdings Ltd through multiple platforms. This information may help you make smarter investment decisions.
About SPHRF
Starpharma Holdings Limited is an Australia-based biotechnology company specializing in advancing dendrimer technology. The Company's principal activities are focused on the research, development and commercialization of dendrimer technology for pharmaceutical and healthcare applications. The Company's portfolio of dendrimer-based products includes three clinical-stage dendrimer enhanced product (DEP) assets, preclinical radiopharmaceutical assets, research collaborations, and three commercially marketed over the counter (OTC) products. Its clinical-stage assets, DEP SN38, DEP cabazitaxel, and DEP docetaxel, are dendrimer-based chemotherapeutic drugs. Additionally, the Company has a preclinical pipeline of DEP radiopharmaceuticals in development. It also manufactures and sells SPL7013 (astodrimer sodium) proprietary products: VivaGel BV, Viraleze nasal spray, and VivaGel condom. The Company has applied its DEP technology to the innovative area of antibody-drug conjugates.